Clinical Trial Update: Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial is evaluating the safety and efficacy of Anlotinib in recurrent craniopharyngioma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craniopharyngioma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Craniopharyngiomas | Phase 1, Phase 2 | Status: RECRUITING